TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16766594

Group type: EXPERIMENTAL
Intervention: 50 mg L-AmB every other day (arm A)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No systemic antifungal prophylaxis (arm B)
Number of subjects: 132
Study: 14651419

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10807830

Group type: EXPERIMENTAL
Intervention: Augmented-support (AS) group, n = 54
Number of subjects: 108

Group type: COMPARATOR
Intervention: Basic-support (BS) group, n = 54
Number of subjects: 108
Study: 9257763

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of isepamicin (1-g dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of isepamicin (1-g dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of isepamicin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of isepamicin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous infusion and intramuscular injection of isepamicin
Number of subjects: 18
Study: 8099791

Group type: EXPERIMENTAL
Intervention: AMPT in a rested condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AMPT plus 40.5 hours of total sleep deprivation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus sleep deprivation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo in a rested condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AMPT plus sleep deprivation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AMPT alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sleep deprivation alone
Number of subjects: 40
Study: 2433016

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP), vincristine, and bleomycin or CDDP and 5‐fluorouracil (5‐FU) infusion
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Cisplatin and 5‐FU infusion combination
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Histologically complete responders who completed local radiation therapy
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Complete response both clinically and histologically
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Advanced nodal disease
Number of subjects: 191
Study: 30354362

Group type: EXPERIMENTAL
Intervention: Everolimus with complete cyclosporine withdrawal
Number of subjects: 115

Group type: COMPARATOR
Intervention: Cyclosporine group
Number of subjects: 115
Study: 27035079

Group type: EXPERIMENTAL
Intervention: PTBD + 3D-CRT
Number of subjects: 37

Group type: COMPARATOR
Intervention: PTBD only
Number of subjects: 37
Study: 24936727

Group type: EXPERIMENTAL
Intervention: 4 g/day omega-3 soft gels
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22469966

Group type: EXPERIMENTAL
Intervention: Music-based listening interventions
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 162
Study: 20400220

Group type: EXPERIMENTAL
Intervention: Gratitude diaries (n=130)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Thought monitoring and restructuring (n=118)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Waitlist control (n=231)
Number of subjects: 479
Study: 18306150

Group type: EXPERIMENTAL
Intervention: Cessation of antipsychotic treatment (haloperidol, risperidone, or olanzapine) for 4 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Continued treatment with antipsychotic drugs for 4 weeks
Number of subjects: 55
Study: 15655101

Group type: EXPERIMENTAL
Intervention: Nurse-led adherence support
Number of subjects: 245

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 245
Study: 11748949

Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 12658

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12658
Study: 9699587

Group type: EXPERIMENTAL
Intervention: Hyperoxic cardiopulmonary bypass (oxygen tension = 400 mm Hg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normoxic cardiopulmonary bypass (oxygen tension = 140 mm Hg)
Number of subjects: 40
Study: 8017358

Group type: EXPERIMENTAL
Intervention: enprostil 35 micrograms twice daily
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: enprostil 35 micrograms three times daily
Number of subjects: 145

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 145
Study: 2598950

Group type: EXPERIMENTAL
Intervention: sustained-release diltiazem (diltiazem-SR) 120 mg b.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: metoprolol 100 mg b.i.d.
Number of subjects: 12
Study: 4219096

Group type: EXPERIMENTAL
Intervention: Disodium ethane 1 hydroxy 1,1 diphosphonate (EHDP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 42
Study: 7446943

Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: thiopentone 6.0 mg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: nitrous oxide in oxygen
Number of subjects: 14
Study: 31823556

Group type: EXPERIMENTAL
Intervention: PRP injection group (group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PRP covered group (group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90
Study: 28327108

Group type: EXPERIMENTAL
Intervention: Ultrasonic Scalpel (USS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 80
Study: 26059497

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/thymol-containing antibacterial varnish (Cervitec(®) Plus; CV group) applied quarterly
Number of subjects: 189

Group type: COMPARATOR
Intervention: Fluoride varnish (Fluor Protector; FV group) applied biannually plus biannual treatments with placebo varnish
Number of subjects: 189
Study: 23916324

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Varenicline (among cigarette smokers)
Number of subjects: 40
Study: 21497318

Group type: EXPERIMENTAL
Intervention: 10-week supervised hip flexor stretching program
Number of subjects: 82

Group type: COMPARATOR
Intervention: 10-week shoulder abductor stretching program
Number of subjects: 82
Study: 20377818

Group type: EXPERIMENTAL
Intervention: Aromatherapy (rosemary and lemon essential oils in the morning, lavender and orange in the evening)
Number of subjects: 28
Study: 17199068

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (n = 99)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (n = 101)
Number of subjects: 200
Study: 15030181

Group type: EXPERIMENTAL
Intervention: Clivarin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 111
Study: 11586996

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ranitidine 300 mg for 7 days
Number of subjects: 50
Study: 9832348

Group type: EXPERIMENTAL
Intervention: Sertraline 50-150 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Amitriptyline 75-225 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 160

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sertraline and Amitriptyline
Number of subjects: 160
Study: 8016944

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 2643773

Group type: EXPERIMENTAL
Intervention: BM 13,177 (thromboxane-receptor antagonist)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aspirin (20 mg twice daily for four weeks)
Number of subjects: 10
Study: 4206181

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30665608

Group type: EXPERIMENTAL
Intervention: MI-CBT
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MI-CBT + CC
Number of subjects: 180

Group type: COMPARATOR
Intervention: E-TAU
Number of subjects: 180
Study: 27873453

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy using the Thinking Skills for Work program combined with supported employment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 26072109

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks (80 mg starting dose, then 80 mg every 2 weeks)
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks (80 mg starting dose, then 80 mg every 4 weeks)
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Etanercept (50 mg twice weekly)
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Ixekizumab (both regimens)
Number of subjects: 2570
Study: 24063420

Group type: EXPERIMENTAL
Intervention: α-galactosidase
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21332456

Group type: EXPERIMENTAL
Intervention: Product C
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Product D
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Product A
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Products A, B, and D
Number of subjects: 121

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 121
Study: 19476198

Group type: EXPERIMENTAL
Intervention: Behavioral counseling and a novel medication
Number of subjects: 753
Study: 17346614

Group type: EXPERIMENTAL
Intervention: CT imaging group (n=26)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional screening group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Study participation (both groups)
Number of subjects: 56
Study: 15054168

Group type: EXPERIMENTAL
Intervention: Small media campaign (role model story posters, billboards, and other merchandise)
Number of subjects: 1630

Group type: EXPERIMENTAL
Intervention: Small media campaign
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Comparison zip codes (control)
Number of subjects: 1630
Study: 12205253

Group type: EXPERIMENTAL
Intervention: Early introduction of oral feeding (initiated 48 hours after achieving full tube feeding, 120 kcal/kg/d)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (oral feeding management left to discretion of attending physicians)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 9839763

Group type: EXPERIMENTAL
Intervention: Donepezil HCl (5 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ketoconazole (200 mg)
Number of subjects: 21
Study: 8018372

Group type: EXPERIMENTAL
Intervention: Hyperfractionation with 1 Gy 3 times a day to a total of 84 Gy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional treatment 2 Gy once a day to a total of 64 Gy
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Hyperfractionated group
Number of subjects: 168
Study: 2491863

Group type: EXPERIMENTAL
Intervention: Oral zinc (50 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 790294

Group type: EXPERIMENTAL
Intervention: New meditation technique using a home-study workbook manual
Number of subjects: 159

Group type: COMPARATOR
Intervention: Customary meditational techniques
Number of subjects: 159
Study: 31845316

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine/morphine (12.5 mg bupivacaine/300 μg morphine)
Number of subjects: 155
Study: 31653138

Group type: EXPERIMENTAL
Intervention: Filial therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no training, only individual counseling)
Number of subjects: 32
Study: 28168715

Group type: EXPERIMENTAL
Intervention: BAY 86-5047
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 25835462

Group type: EXPERIMENTAL
Intervention: Culturally targeted multi‐component intervention
Number of subjects: 95
Study: 22592540

Group type: EXPERIMENTAL
Intervention: Immediate access to web-based tutorial (Child Health Matters, CHM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group (delayed access)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based tutorial (Child Health Matters, CHM)
Number of subjects: 0
Study: 21783443

Group type: EXPERIMENTAL
Intervention: Thin ideal video
Number of subjects: 138

Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 138
Study: 19968215

Group type: COMPARATOR
Intervention: Late surgical group (surgery >=325 days)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Early surgical group (surgery 324 days prior)
Number of subjects: 42
Study: 17958901

Group type: EXPERIMENTAL
Intervention: PG-116800 25 mg, taken twice daily for 12 months
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: PG-116800 50 mg, taken twice daily for 12 months
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: PG-116800 100 mg, taken twice daily for 12 months
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: PG-116800 200 mg, taken twice daily for 12 months
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: PG-116800 (all doses combined)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: PG-116800 (200 mg group)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: PG-116800 (two highest dose groups)
Number of subjects: 401
Study: 15250819

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11716450

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 200 mg/day for 3 days in 500 ml of saline over 3‐4 hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 36
Study: 9378191

Group type: EXPERIMENTAL
Intervention: AMI patients at 6 weeks post-event
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: AMI patients at 6 months post-event
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Overall evaluation of quality of life and health
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Women with AMI
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Elderly patients with AMI
Number of subjects: 1941
Study: 8329676

Group type: EXPERIMENTAL
Intervention: Placebo/meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo/no meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine/meal
Number of subjects: 10
Study: 3755516

Group type: EXPERIMENTAL
Intervention: Phenobarbital administered to mothers in doses sufficient to achieve blood levels of 15 to 40 micrograms/mL
Number of subjects: 150

Group type: COMPARATOR
Intervention: No antenatal treatment (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Phenobarbital administered to mothers
Number of subjects: 150
Study: 28942461

Group type: EXPERIMENTAL
Intervention: Total Thyroidectomy (TT)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Dunhill Operation (DO)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Bilateral Subtotal Thyroidectomy (BST)
Number of subjects: 600
Study: 26363446

Group type: EXPERIMENTAL
Intervention: Gain-frame email intervention
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Loss-frame email intervention
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Long-term consequence email intervention
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Short-term consequence email intervention
Number of subjects: 220
Study: 25169488

Group type: EXPERIMENTAL
Intervention: rh‐endostatin + DP regimen
Number of subjects: 20

Group type: COMPARATOR
Intervention: single chemotherapy
Number of subjects: 20
Study: 23195004

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia + general anesthesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 46
Study: 20951443

Group type: COMPARATOR
Intervention: Group P (propofol, fentanyl, succinylcholine)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Group J (propofol, fentanyl, succinylcholine + manual jet ventilation with Manujet III)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Group S (propofol and γ‐hydroxybutyrate sodium)
Number of subjects: 360
Study: 17628435

Group type: EXPERIMENTAL
Intervention: Buspirone, 30 mg/day
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 15668419

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (IFNbeta‐1a), administered once-weekly via intramuscular injection.
Number of subjects: 386
Study: 11978276

Group type: EXPERIMENTAL
Intervention: Early oral analgesia (20 mg every 4 hours, additional 10 mg every 2 hours as needed)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Traditional parenteral analgesia (parenteral morphine via PCA pump with basal dose of 0.5 mg/h and PCA dose of 1 mg)
Number of subjects: 227
Study: 10544763

Group type: EXPERIMENTAL
Intervention: Endoscopic axillary lymphadenectomy after liposuction
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional surgical lymphadenectomy
Number of subjects: 152
Study: 7557770

Group type: EXPERIMENTAL
Intervention: Guttapercha
Number of subjects: 500

Group type: COMPARATOR
Intervention: Titan pins
Number of subjects: 500
Study: 1351127

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 50
Study: 3909118

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30009473

Group type: EXPERIMENTAL
Intervention: Proenkephalin (PENK) measured at baseline and on day 1 after contrast media administration
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Delta PENK (change in PENK levels)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Area under the curve (AUC) for prediction of AKI by day 1 PENK
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Area under the curve (AUC) for prediction of AKI by delta PENK
Number of subjects: 111
Study: 27534729

Group type: EXPERIMENTAL
Intervention: Structured elaborative feedback during visual shade matching
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no elaborative feedback)
Number of subjects: 60
Study: 26270115

Group type: EXPERIMENTAL
Intervention: Preprocedural ultrasound-guided paramedian technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional landmark-guided midline approach
Number of subjects: 100
Study: 23591789

Group type: EXPERIMENTAL
Intervention: DA+GO (daunorubicin 45 mg/m(2) on days 1-3, cytarabine 100 mg/m(2) continuous infusion on days 1-7, GO 6 mg/m(2) on day 4)
Number of subjects: 637

Group type: COMPARATOR
Intervention: DA (daunorubicin 60 mg/m(2) on days 1-3, cytarabine alone)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: DA+GO (postconsolidation therapy with 3 doses of GO 5 mg/m(2) every 28 days)
Number of subjects: 637

Group type: COMPARATOR
Intervention: DA (postconsolidation therapy with no additional therapy)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: DA+GO
Number of subjects: 637

Group type: COMPARATOR
Intervention: DA
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Postconsolidation GO
Number of subjects: 637
Study: 20874057

Group type: EXPERIMENTAL
Intervention: Talking Mats
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Verbally structured communication
Number of subjects: 5

Group type: COMPARATOR
Intervention: Unstructured communication
Number of subjects: 5
Study: 18378631

Group type: COMPARATOR
Intervention: Glimepiride, 1 to 4 mg
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Pioglitazone, 15 to 45 mg
Number of subjects: 543

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 543
Study: 16616230

Group type: EXPERIMENTAL
Intervention: edifoligide
Number of subjects: 1404

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: overall cohort
Number of subjects: 1404
Study: 12798527

Group type: EXPERIMENTAL
Intervention: Phytoestrogens (tablets containing 114 mg of isoflavonoids)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Phytoestrogens
Number of subjects: 62
Study: 11307095

Group type: EXPERIMENTAL
Intervention: Ceftibuten (400 mg) given orally, single dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (1000/200 mg) given by intravenous infusion, three doses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 100
Study: 7644448

Group type: EXPERIMENTAL
Intervention: Self-report of practice
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ability to detect lumps in a model
Number of subjects: 81
Study: 2528295

Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant DNA hepatitis B vaccine (20 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant DNA hepatitis B vaccine (40 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant DNA hepatitis B vaccine (zero, one, two, six months schedule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant DNA hepatitis B vaccine (zero, one, two, twelve months schedule)
Number of subjects: 0
Study: 391629

Group type: EXPERIMENTAL
Intervention: Compound analgesic with chlormezanone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Compound analgesic (placebo-controlled)
Number of subjects: 0
Study: 31960066

Group type: EXPERIMENTAL
Intervention: Myomo + repetitive, task-specific practice
Number of subjects: 34

Group type: COMPARATOR
Intervention: Repetitive, task-specific practice only
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Myomo only
Number of subjects: 34
Study: 30839428

Group type: EXPERIMENTAL
Intervention: Simulated opioid-tapering advice
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Simulated opioid-change advice
Number of subjects: 196

Group type: COMPARATOR
Intervention: Simulated opioid-maintenance advice
Number of subjects: 196